Project Grant HT94252410015
Award Date
11/15/23
Completion Date
11/14/25
Dollars Obligated
$332K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Los Angeles, CA 90089, USA
Similar Awards
The University of Southern California (USC) was awarded a $2,490,000 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the development of a VAV2 antisense oligonucleotide therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to advance innovative biomedical research focused on transforming healthcare for military service members and the broader public. The award...
The University of Southern California (USC) was awarded a $915,936 Project Grant from the U.S. Department of Defense's Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The funding supports research to investigate SETD2 deficiency as a therapeutic target to upregulate viral mimicry for treating aggressive clear cell renal cell carcinoma in patients. This award is part of the program's focus on cancer, neurological disorders, and other health...
The University of Southern California (USC) received a $828,538 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on "MICRORNA THERAPY TARGETING FIBROTIC SCAR FORMATION FOR IMPROVEMENT OF COGNITIVE FUNCTION AFTER TRAUMATIC BRAIN INJURY". The award has a performance period from May 1, 2024 to April 30, 2027. The funded research aims to develop novel microRNA-based therapies to address fibrotic...
This federal Project Grant award of $1,992,000.00, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, funds the development of a "Synthetic Immune Receptor for the Treatment of Prostate Cancer" at the University of Southern California (USC). The award, with a performance period from September 15, 2025 to September 14, 2028, supports advanced biomedical research focused on transforming healthcare for military service members...
The University of Southern California (USC) was awarded a $3,296,634.00 Project Grant from the Defense Health Agency to conduct research on "ACTIVATION OF BRAIN LYMPHATIC DRAINAGE THROUGH PIEZO1-CONTROLLED MECHANOTRANSDUCTION AS A NOVEL HYDROCEPHALUS THERAPY". The grant, which commenced on September 1, 2023 and will be completed by August 31, 2027, is funded through the Military Medical Research and Development (CFDA 12.420) program. This research aims to investigate medical...
The Department of Defense awarded a $3,166,177 Cooperative Agreement to the University of Southern California (USC) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2023. This funding supports the "Convergent Science Cancer Consortium" project, which aims to transform healthcare for Service Members and the American public through innovative biomedical research on cancer and other disease areas. As part of this effort, USC has sub-awarded...
This $1,113,749 Project Grant awarded by the Defense Health Agency (CFDA 12.420 - Military Medical Research and Development) to the University of Southern California (USC) supports the development of Synthetic Immune Receptor T (SIR-T) cells targeting the B7-H3 protein for the treatment of renal cancer. The grant, which commenced on September 15, 2023, will fund a 3-year research project to explore this novel immunotherapeutic approach for addressing renal cancer. As a leading private research...
The University of Southern California will receive $330,000 under a two-year Project Grant award from the Department of the Army Medical Command. The grant falls under the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to improve military and public health care. Through this funding, USC will validate PIKFYVE inhibition as a therapeutic approach for diverse forms of frontotemporal dementia from March 2021 to...
The University of Southern California (USC) was awarded a $220,412.84 Project Grant from the Department of Defense Basic Scientific Research program (CFDA 12.431) with a performance period from September 1, 2024 to August 31, 2027. The grant supports foundational and applied research across diverse scientific and technical domains critical to national security, including areas such as quantum computing, artificial intelligence, materials science, robotics, defense technologies, and behavioral...
The University of Southern California will receive $165,000 under a Project Grant award from the Defense Health Agency to investigate using WEE1 inhibitor to convert immune cold tumors into immune hot tumors for aggressive clear cell renal cell carcinoma with SETD2 deficiency. The grant period runs from April 1, 2023 to March 31, 2024. This award falls under the Military Medical Research and Development program (CFDA 12.420) which supports basic, applied, and advanced biomedical research to...